Household economic impact of HIV‐associated cryptococcal meningitis in five countries in Southern and Eastern Africa
Journal of the International AIDS Society · 2025
DOI: 10.1002/jia2.26441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von David S Lawrence und 32 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, HIV Infections, Health Expenditures, AIDS-Related Opportunistic Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, FIC NIH HHS, National Institute for Health and Care Research.
Abstract (Originalsprache)
Introduction
HIV‐associated cryptococcal meningitis is the second leading cause of AIDS‐related mortality. Cryptococcal meningitis is a poverty‐related disease and the majority of cases occur in settings where resources are limited and access to quality care is often linked to an individual's ability to pay for services. We have previously demonstrated the efficacy, safety and cost‐effectiveness of a single, high‐dose liposomal amphotericin‐based treatment regimen within the AMBITION‐cm trial. Here, we present a five‐country, within‐trial analysis exploring the household economic impact of cryptococcal meningitis.
Methods
Eight hundred and ten participants were recruited into this sub‐study in Botswana, Malawi, South Africa, Uganda and Zimbabwe between January 2018 and February 2021. We collected data on annual household expenditure, direct costs and indirect costs incurred prior to enrolment and during the 10‐week trial period. Costs were inflated and converted to 2022 USD. We calculated out‐of‐pocket expenditure, lost income and catastrophic healthcare expenditure, defined as costs exceeding 20% of annual household expenditure.
Results
The average total out‐of‐pocket expenditure plus lost income prior to enrolment was $132 and 17.9% (145/810, 95% CI 15.3–20.5) of participant households had already experienced catastrophic healthcare expenditure. Among the 592 surviving participants, when combining out‐of‐pocket expenditure and lost income, the average cost was $516 and 29.1% of annual household expenditure across all countries, ranging from $230 (7.6%) in South Africa to $592 (64.2%) in Zimbabwe. More than half (296/581, 51.0%, 95% CI 46.9–55.0) of households experienced catastrophic healthcare expenditure by the end of the trial, ranging from 16.0% (13/81, 95% CI 7.9–24.2) in South Africa to 68.1% (156/229, 95% CI 62.0–74.2) in Uganda.
Conclusions
This is the first study exploring the household economic impact experienced by those diagnosed with cryptococcal meningitis. The household economic impact of cryptococcal meningitis is high and more than half of households of individuals who survive experience catastrophic healthcare expenditure. It is likely these figures are higher outside of the research setting. This highlights the profound financial impact of this devastating infection and provides a rationale to offer financial and social protection to those affected. Trial Registration Number ISRCTN72509687
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
- Botswana Harvard Health Partnership, Gaborone, Botswana.
- Institute for Infection and Immunity, St George's, University London, London, UK.
- Health Economics Unit and Division, School of Public Health, Health Sciences Faculty, University of Cape Town, Cape Town, South Africa.
- Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
- University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: David S Lawrence, Mina C Hosseinipour, Tshepo B Leeme, David B Meya, Lucy Cunnama
Förderung
- Wellcome Trust
- FIC NIH HHS
- National Institute for Health and Care Research
- Department of Science and Technology, Republic of South Africa
- European and Developing Countries Clinical Trials Partnership
- Medical Research Council
Zitieren
APA
Lawrence, D. S., Muthoga, C., Adams, J., Ndweni, A. B., Boulware, D. R., Chawinga, C., Comins, K., Dziwani, E. N., Hlupeni, A., Hosseinipour, M. C., Jjunju, S., Kanyama, C., Leeme, T. B., Meintjes, G., Meya, D. B., Mosepele, M., Moyo, M., Mwandumba, H. C., Muzoora, C., …, & AMBITION Study Group (2025). Household economic impact of HIV‐associated cryptococcal meningitis in five countries in Southern and Eastern Africa. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26441
Vancouver
Lawrence DS, Muthoga C, Adams J, Ndweni AB, Boulware DR, Chawinga C, et al. Household economic impact of HIV‐associated cryptococcal meningitis in five countries in Southern and Eastern Africa. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.26441
BibTeX
@article{Lawrence2025,
author = {Lawrence, David S and Muthoga, Charles and Adams, Jack and Ndweni, Antoinette Buhle and Boulware, David R and Chawinga, Chimwemwe and Comins, Kyla and Dziwani, Eltas N and Hlupeni, Admire and Hosseinipour, Mina C and Jjunju, Samuel and Kanyama, Cecilia and Leeme, Tshepo B and Meintjes, Graeme and Meya, David B and Mosepele, Mosepele and Moyo, Melanie and Mwandumba, Henry C and Muzoora, Conrad and Ndhlovu, Chiratidzo E and Nuwagira, Edwin and Schutz, Charlotte and Tugume, Lillian and Williams, Darlisha and Molloy, Síle F and Boyer-Chammard, Timothée and Youssouf, Nabila and Jaffar, Shabbar and Niessen, Louis W and Harrison, Thomas S and Cunnama, Lucy and Jarvis, Joseph N and AMBITION Study Group, AMBITION Study Group},
title = {Household economic impact of HIV‐associated cryptococcal meningitis in five countries in Southern and Eastern Africa},
journal = {Journal of the International AIDS Society},
year = {2025},
doi = {10.1002/jia2.26441}
}
EUVIMED